SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis
- 12 October 2021
- journal article
- review article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (4), 210-223
- https://doi.org/10.1016/j.clml.2021.10.002
Abstract
No abstract availableThis publication has 127 references indexed in Scilit:
- Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm CellsMolecular Cancer Therapeutics, 2013
- One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic ExperienceMayo Clinic Proceedings, 2012
- Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm CellsClinical Cancer Research, 2011
- JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasmsOncogene, 2011
- JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes MyeloproliferationCancer Cell, 2011
- HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humansJCI Insight, 2010
- Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSSHaematologica, 2010
- Low-dose thalidomide in myelofibrosisHaematologica, 2008
- Low-Dose Thalidomide Ameliorates Cytopenias and Splenomegaly in Myelofibrosis With Myeloid Metaplasia: A Phase II TrialJournal of Clinical Oncology, 2004
- A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasiaBlood, 2003